
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
This trial is looking at a new drug called DTP3 for diffuse large B cell lymphoma or myeloma.
It is for people whose treatment has stopped working or their cancer has got worse.
There are a number of ways to treat diffuse large B cell lymphoma or myeloma. Myeloma is also called multiple myeloma.
Sometimes the cancer comes back after treatment or treatment stops working. Doctors are looking at new treatments to help these groups of people. In this trial, they are looking at a new drug called DTP3.
DTP3 is a . It aims to kill myeloma or lymphoma cells without affecting normal cells. It might have fewer side effects.
The main aims of the trial are to:
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
For people who have myeloma the following must apply. You:
For people who have diffuse large B cell lymphoma the following must apply. You:
As well as the above entry conditions for myeloma and lymphoma, the following must also apply. You:
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
Medical conditions
You cannot join this trial if any of these apply. You:
Other
You cannot join this trial if you are pregnant or breastfeeding.
This is a phase 1/2 trial. The researchers would like up to 72 people across the UK to take part. This trial has 2 parts:
Dose escalation
The team need about 24 people with either myeloma or lymphoma to join the dose escalation part. The first few people taking part have a low dose of DTP3. The next few people have a higher dose if they don’t have any serious side effects. And so on, until doctors find the best dose. This dose is one that helps the most and has the fewest side effects
Dose expansion
The researchers need about 24 people with myeloma and 24 with lymphoma to join this part. This part opens when they find the best dose in part 1.
How you have treatment
You have DTP3 as a drip into a vein. It takes about an hour each time. You have treatment three times a week on the hospital day care ward. This is likely to be on a Monday, Wednesday and Friday. The team can tell you more about this. Everyone has treatment for as long as it is working and the side effects aren’t too bad.
Samples for research
The researchers ask you to give some extra blood samples. Where possible, you have these at the same time as your routine blood tests. They also ask to look at samples of or samples of cancer tissue (b
) your doctor may ask for.
They plan to use the samples to:
You see the doctor and have tests before you can take part. These include:
After the first treatment, you may have an overnight stay in the hospital. This is so the team can take some blood samples to see what happens to DTP3 in the body. If you are unable to stay overnight, they take samples from you on the day care ward. These would stop at the end of the first day, to allow you to return home.
You have one extra bone marrow test or biopsy of cancer tissue. You have this during your third week of treatment.
You have regular check ups and blood tests during treatment.
Follow up
When you stop treatment, you see the team at your routine hospital appointments. This is to check how you are and if you have started another cancer treatment.
The team phone you every 6 weeks to see how you are if you aren’t having hospital appointments.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Only a few people have had DTP3 in the past and in this study. So the team are not sure what the side effects are. You see the doctor regularly to see if there are any side effects. We’ll add information about these when we know more.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Aris Chaidos
Imperial College London
Institute of Cancer Research (ICR)
Medical Research Council (MRC)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.